Page 3 - Pharma

Bugworks Research gets $18mn funding as it scales up clinical research

The Series B1 financing was led by Lightrock India

What are Lupin CEO Vinita Gupta's plans for growth in US & China?

In conversation with Business Standard's Sohini Das, Lupin CEO Vinita Gupta shared her company's growth plans in the US and in China. Let us listen in to the interview

Fewer launches subdue pharma market's Dec sequential growth

As per India Ratings and Research (Ind-Ra), IPM continued to deliver slower growth of 5.3 per cent YoY in December 2021 after growing 6.6 per cent in November 2021

Emcure Pharma's Rs 5,000-crore IPO to hit market early next month

Emcure Pharmaceuticals has received regulatory approvals for its draft red herring prospectus and will shortly be filing the RHP for the Rs 5,000-crore initial share sale, which will hit the market soon after the Budget, according to merchant banking sources. The IPO consists of a fresh issue of up to Rs 1,100 crore by the company, which will be used as growth capital, and an offer for sale by promoter shareholders -- founder, managing director & chief executive Satish Mehta who owns 41.92 per cent and by son Sunil Mehta who holds 6.13 per cent. Other promoter groups/persons who are participating in the OFS collectively own 33.55 per cent, and global private equity major Bain Capital owns 13.09 per cent in the Pune-headquartered pharma major which is the 12th largest player in the country. The sources, however, did not disclose how much each of the selling promoters will be offloading through the OFS. The company will utilize Rs 947 crore from the proceeds of the issue to ...

Granules India gets USFDA nod for its generic Amphetamine mixed salts

This is for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy

Pharma players to launch anti-Covid pill shortly after DCGI approval

Homegrown pharma majors Sun Pharma, Cipla, Hetero, Torrent announced plans to market their versions of antiviral drug Molnupiravir to treat high-risk adult patients with Covid across India shortly.

Trials start for Equillium drug for autoimmune disease after India approval

Equillium secured exclusive rights to develop and commercialise itolizumab for the US and Canada markets, in May 2017.

Diagnostic industry may log 55% revenue growth in FY22, says report

The report by Icra Ratings also expects the prices of diagnostic tests to stabilise at current levels due to focus on volume growth and higher competitive intensity from unorganized players

Supriya Lifescience IPO fully subscribed within few hours of opening

On Wednesday, the company raised Rs 315 crore from anchor investors

Medical device, pharmaceutical units in NCR allowed to use diesel gensets

Factories making pharmaceuticals, medical devices, life saving medical equipment can use diesel gensets to run their plants, said the Commission for Air Quality Management in NCR & Adjoining Areas.

Bill to enhance status of 6 institutes of pharma edu, research gets Parl OK

The National Institute of Pharmaceutical Education and Research (Amendment) Bill, 2021, passed by the Lok Sabha on December 6, was cleared in the Rajya Sabha on Thursday with a voice vote

Dr Reddy's launches drug in US to treat high blood pressure, heart failure

The tablet is the generic therapeutic equivalent of Diovan, approved by the US Food and Drug Administration

IT, pharma segments may not provide hedge if rupee weakens

There are concerns over margin and growth, which may weigh on sentiment

Alembic Pharma gets USFDA nod for formoterol fumarate inhalation solution

Alembic Pharmaceuticals Ltd on Tuesday said it has received final approval from the US Food & Drug Administration (USFDA) for its generic version of formoterol fumarate inhalation solution used for the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. The approval for the abbreviated new drug application (ANDA) for formoterol fumarate inhalation solution is for 20 mcg/2 ml per unit-dose vial. It is therapeutically equivalent to Mylan Specialty's 'Perforomist Inhalation Solution', 20 mcg/2 ml per unit-dose vial, Alembic Pharmaceuticals said in a regulatory filing. The formoterol fumarate inhalation solution indicated for long term, twice daily -- morning and evening -- administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, it added. "This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies Pvt .

Zydus Cadila gets USFDA nod to market generic cancer drug in US

The drug will be manufactured at the group's injectables manufacturing facility

Our aim is to create ecosystem to make India lead in drug discovery: PM

India has a large pool of scientists and technologists with a potential to take the industry to greater heights, says PM Modi at Global Innovation Summit of the Pharmaceuticals sector

Piramal Enterprises board approves to demerge and list pharma business

The demerger will give potential investors the option of being associated with the business of their choice

MakeMyTrip sees 100% return to travel in pharma, realty, other corp sectors

Firm's recent market study says financial services, IT, consumer goods and auto are the laggards, may be the last ones to see a complete recovery in corporate travel

Charting growth: Acute therapy drugs make a comeback in July, shows data

But a fall in doctor visits hit acute therapy drugs. July saw a major turnaround

Biocon partners Adagio for licence to make Covid-19 antibody cocktail

Treatment claims to address the resistant Delta variant as well